8.93
1.54 (20.84%)
| Previous Close | 7.39 |
| Open | 7.50 |
| Volume | 34,146 |
| Avg. Volume (3M) | 16,859 |
| Market Cap | 78,510,328 |
| Price / Earnings (TTM) | 63.79 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2024 - 12 Aug 2024 |
| Profit Margin | -232.86% |
| Operating Margin (TTM) | -37,942.86% |
| Diluted EPS (TTM) | 0.160 |
| Quarterly Revenue Growth (YOY) | -53.10% |
| Quarterly Earnings Growth (YOY) | -19.60% |
| Current Ratio (MRQ) | 0.400 |
| Operating Cash Flow (TTM) | -12.43 M |
| Levered Free Cash Flow (TTM) | -7.45 M |
| Return on Assets (TTM) | -86.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Serina Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.25 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 58.40% |
| % Held by Institutions | 3.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Strategic Wealth Investment Group, Llc | 31 Dec 2023 | 2,768 |
| Piscataqua Savings Bank | 30 Jun 2024 | 28 |
| Riggs Asset Managment Co. Inc. | 31 Mar 2024 | 24 |
| Albion Financial Group /Ut | 30 Jun 2024 | 8 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Dec 2024 | Announcement | Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 |
| 11 Dec 2024 | Announcement | Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit |
| 02 Dec 2024 | Announcement | Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients |
| 12 Nov 2024 | Announcement | Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights |
| 11 Nov 2024 | Announcement | Serina Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 02 Oct 2024 | Announcement | Serina Therapeutics to Present at the 14th Annual Injectables Summit |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |